PRKN and glioblastoma: The significance of PARK2 mutations in various cancers, including GBM, lies in the fact that the subsequent decrease in PARK2’s E3 ligase activity compromises its ability to ubiquitinate cyclin E and thereby results in mitotic instability [29,30].